三月田 祐平

Medicine & Life Sciences

1. Glioblastoma 100%
2. Glioma 71%
3. Bevacizumab 54%
4. Mutation 38%
5. Isocitrate Dehydrogenase 32%
6. Temozolomide 27%
7. Oligodendroglioma 25%
8. Survival 20%
9. Neoplasms 19%
10. Elderly 17%
11. Ganglioglioma 14%
12. Epigenome 12%
13. Septum Pellucidum 11%
14. Clinical Deterioration 11%
15. Central Nervous System Neoplasms 11%
16. hydrogen sulfite 10%
17. Histones 10%
18. Cerebellopontine Angle 10%
19. Lab-On-A-Chip Devices 10%
20. Retrospective Studies 10%
21. Craniopharyngioma 10%
22. Brain Neoplasms 10%
23. Rivaroxaban 9%
24. Temporal Arteries 9%
25. Whole Genome Sequencing 9%
26. Japan 9%
27. Single-Stranded DNA 9%
28. Horns 9%
29. Salvage Therapy 9%
30. Pediatrics 9%
31. Diffusion Magnetic Resonance Imaging 8%
32. Partial Epilepsy 8%
33. Neurilemmoma 8%
34. Status Epilepticus 8%
35. Freezing 8%
36. Gadolinium 8%
37. Lateral Ventricles 8%
38. Facial Nerve 8%
39. Meningioma 8%
40. Middle Cerebral Artery 8%
41. Mucins 8%
42. Chemoradiotherapy 8%
43. Drug Therapy 7%
44. Microglia 7%
45. Thrombocytopenia 7%
46. Temporal Lobe 7%
47. Ligation 6%
48. Cerebrospinal Fluid 6%
49. Recurrence 6%